
iCAD, Inc. – NASDAQ:ICAD
iCAD stock price today
iCAD stock price monthly change
iCAD stock price quarterly change
iCAD stock price yearly change
iCAD key metrics
Market Cap | 46.97M |
Enterprise value | N/A |
P/E | -2.6 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 1.28 |
Price/Book | 1.03 |
PEG ratio | 0.06 |
EPS | -0.11 |
Revenue | 19.63M |
EBITDA | -4.58M |
Income | -2.98M |
Revenue Q/Q | -14.26% |
Revenue Y/Y | -25.05% |
Profit margin | -49.29% |
Oper. margin | -49.85% |
Gross margin | 70.9% |
EBIT margin | -49.85% |
EBITDA margin | -23.35% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeiCAD stock price history
iCAD stock forecast
iCAD financial statements
Jun 2023 | 5.86M | -1.75M | -29.84% |
---|---|---|---|
Sep 2023 | 4.07M | -1.37M | -33.73% |
Dec 2023 | 4.74M | 1.36M | 28.73% |
Mar 2024 | 4.95M | -1.22M | -24.67% |
Sep 2025 | 5.06M | -1.60M | -31.62% |
---|---|---|---|
Oct 2025 | 5.06M | -1.55M | -30.73% |
Dec 2025 | 5.46M | -1.43M | -26.26% |
Mar 2026 | 5.38M | -1.08M | -20.2% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 44832000 | 14.65M | 32.7% |
---|---|---|---|
Sep 2023 | 45828000 | 14.79M | 32.28% |
Dec 2023 | 41418000 | 8.00M | 19.32% |
Mar 2024 | 40395000 | 7.93M | 19.64% |
Jun 2023 | -405K | -221K | 46K |
---|---|---|---|
Sep 2023 | -1.58M | -332K | 1.92M |
Dec 2023 | -1.45M | 3.95M | 125K |
Mar 2024 | -1.18M | -206K | 0 |
iCAD alternative data
Aug 2023 | 108 |
---|---|
Sep 2023 | 108 |
Oct 2023 | 108 |
Nov 2023 | 108 |
Dec 2023 | 108 |
Jan 2024 | 108 |
Feb 2024 | 108 |
Mar 2024 | 108 |
Apr 2024 | 108 |
May 2024 | 67 |
Jun 2024 | 67 |
Jul 2024 | 67 |
iCAD other data
Period | Buy | Sel |
---|---|---|
Sep 2022 | 0 | 38960 |
Mar 2023 | 40000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | BROWN DANA R director, officer: See Remarks | Common Stock | 40,000 | $1.3 | $52,000 | ||
Option | GO JONATHAN officer: Chief Te.. | Employee Stock Option (Right to Buy) | 45,000 | $2.27 | $102,150 | ||
Sale | GO JONATHAN officer: Chief Te.. | Common Stock | 1,080 | $2.65 | $2,862 | ||
Sale | GO JONATHAN officer: Chief Te.. | Common Stock | 37,880 | $2.74 | $103,791 | ||
Option | GO JONATHAN officer: Chief Te.. | Common Stock | 45,000 | $2.27 | $102,150 | ||
Option | GO JONATHAN officer: Chief Te.. | Employee Stock Option (Right to Buy) | 20,000 | $2.9 | $58,000 | ||
Purchase | IRISH TIMOTHY NORRIS director | Common Stock | 5,500 | $4.63 | $25,465 | ||
Sale | SASSINE ANDY director | Common Stock | 10,000 | $5.49 | $54,900 | ||
Sale | SASSINE ANDY director | Common Stock | 10,000 | $5.26 | $52,600 | ||
Option | GO JONATHAN officer: Chief Te.. | Common Stock | 20,000 | $2.9 | $58,000 |
Patent |
---|
Application Filling date: 22 Nov 2019 Issue date: 28 May 2020 |
Grant Filling date: 1 Apr 2015 Issue date: 15 Oct 2019 |
Grant Filling date: 10 Nov 2014 Issue date: 13 Aug 2019 |
Quarter | Transcript |
---|---|
Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 12 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Michael S. Klein (1954) Executive Chairman & Chief Executive Officer | $621,020 |
Ms. Stacey M. Stevens (1968) Pres | $484,830 |
Mr. Jonathan Go (1963) Chief Technology Officer | $416,340 |
-
What's the price of iCAD stock today?
One share of iCAD stock can currently be purchased for approximately $3.87.
-
When is iCAD's next earnings date?
Unfortunately, iCAD's (ICAD) next earnings date is currently unknown.
-
Does iCAD pay dividends?
No, iCAD does not pay dividends.
-
How much money does iCAD make?
iCAD has a market capitalization of 46.97M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 38.03% to 17.32M US dollars.
-
What is iCAD's stock symbol?
iCAD, Inc. is traded on the NASDAQ under the ticker symbol "ICAD".
-
What is iCAD's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of iCAD?
Shares of iCAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are iCAD's key executives?
iCAD's management team includes the following people:
- Mr. Michael S. Klein Executive Chairman & Chief Executive Officer(age: 71, pay: $621,020)
- Ms. Stacey M. Stevens Pres(age: 57, pay: $484,830)
- Mr. Jonathan Go Chief Technology Officer(age: 62, pay: $416,340)
-
How many employees does iCAD have?
As Jul 2024, iCAD employs 67 workers, which is 38% less then previous quarter.
-
When iCAD went public?
iCAD, Inc. is publicly traded company for more then 40 years since IPO on 13 Dec 1984.
-
What is iCAD's official website?
The official website for iCAD is icadmed.com.
-
Where are iCAD's headquarters?
iCAD is headquartered at 98 Spit Brook Road, Nashua, NH.
-
How can i contact iCAD?
iCAD's mailing address is 98 Spit Brook Road, Nashua, NH and company can be reached via phone at +60 38825200.
iCAD company profile:

iCAD, Inc.
icadmed.comNASDAQ
67
Medical - Devices
Healthcare
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Nashua, NH 03062
CIK: 0000749660
ISIN: US44934S2068
CUSIP: 44934S206